NASDAQ:CGEM
Cullinan Oncology, Inc. Stock News
$23.03
-1.10 (-4.56%)
At Close: May 28, 2024
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
05:30pm, Tuesday, 08'th Mar 2022
Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference
06:30am, Monday, 07'th Feb 2022
CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink's 11th Annual Global Healthcare
Cullinan Oncology Stock (CGEM): Why The Price Increased
01:37am, Wednesday, 05'th Jan 2022
The stock price of Cullinan Oncology Inc (NASDAQ: CGEM) increased by 1.58% in the most recent trading session. This is why it happened.
Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients
01:04pm, Thursday, 16'th Dec 2021
Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial includes patients whose tumors harb
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
07:00am, Monday, 18'th Oct 2021
Ahmed's appointment brings broad development and operational leadership experience to Cullinan, reflecting the advancement of its pipeline and transition to a later-stage oncology company Ahmed's appo
Cullinan Oncology to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 08'th Sep 2021
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences:
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
06:30am, Tuesday, 10'th Aug 2021
Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort
Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
12:44pm, Wednesday, 30'th Jun 2021
Cullinan is building a unique hub-and-spoke business model in drug development to build more efficient and scalable pipelines. The company has already built out a pipeline of 7 assets and got the mode
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data
10:32am, Monday, 07'th Jun 2021
Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.
Why Cullinan Oncology Stock Is Skyrocketing Today
11:53am, Friday, 04'th Jun 2021
The company announced encouraging clinical data for its experimental lung cancer drug.
Cullinan Oncology Announces Management Transition
08:00am, Friday, 21'st May 2021
CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today a
Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021
05:00pm, Wednesday, 19'th May 2021
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today a
Cullinan Oncology Reports First Quarter 2021 Financial Results
06:30am, Friday, 14'th May 2021
Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations
Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
10:08am, Wednesday, 07'th Apr 2021
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company's Chief Financial Officer, Jeff Trigilio, will present at
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights
06:15am, Tuesday, 30'th Mar 2021
Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Flore
